Neoplasms

All Conditions

Adenocarcinoma

Carcinoma

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Different doses of fruquintinib combined with sintilimab and CAPEOX

Fruquintinib in combination with Sintilimab and CAPEOX

Xiaobing Chen

Based on the current status and progress in the treatment of gastric cancer, our center prospectively designed a first-line comprehensive treatment plan for unresectable or postoperative recurrent advanced gastric/gastroesophageal conjoint adenocarcinoma, fruquintinib + sintilimab + oxaliplatin + Capecitabine (CAPEOX), which utilizes the tumor immunomodulation and vascular normalization effects of fruquintinib. While improving the effective perfusion of intravenous chemotherapy with CAPEOX regimen, further combining with PD-1 monoclonal antibody to regulate the immunosuppressive microenvironment and reactivate the anti-tumor immune response of the body. An exploratory dose-climbing trial was designed to evaluate the clinical efficacy and safety of fruquintinib in combination with Sintilimab and CAPEOX in clinical practice. At the same time, changes in genome, pathology and immune microenvironment of tumor-related tissues before and after treatment were observed, and molecular markers related to curative effect were screened to explore the molecular mechanism affecting the curative effect of combination therapy, and further enrichment of therapeutic advantage groups to improve the surgical conversion rate laid the foundation for future large-scale clinical studies

Fruquintinib in Combination With Sintilimab and CAPEOX as First-line Treatment for G/GEJ Cancer

A Single-arm, Open-label, Multicenter, Phase Ib/II Study to Evaluate the Safety and Efficacy of Fruquintinib in Combination With Sintilimab and CAPEOX as 1L Treatment for Advanced Unresectable or Metastatic G/GEJ Cancer (FUNCTION Research)

It refers to the proportion of patients whose tumors have shrunk to a certain extent for a certain period of time, including CR and PR cases

Refers to the maximum tolerated dose of the whole group

Refers to the date from admission to death from any cause

Refers to the date from admission to the first onset of disease progression or death from any cause, whichever comes first

Refers to the percentage of confirmed complete response, partial response, and stable disease cases in patients evaluated for efficacy

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Fruquintinib in Combination With Sintilimab and CAPEOX as First-line Treatment for G/GEJ Cancer	NCT06329973	Metastatic Gast...	Fruquintinib in...	18 Years - 75 Years	Henan Cancer Hospital
Fruquintinib in Combination With Sintilimab and CAPEOX as First-line Treatment for G/GEJ Cancer	NCT06329973	Metastatic Gast...	Fruquintinib in...	18 Years - 75 Years	Henan Cancer Hospital

Spots Global Cancer Trial Database for fruquintinib in combination with sintilimab and capeox